

# Barzin Y Nabet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4705315/publications.pdf>

Version: 2024-02-01

22  
papers

3,729  
citations

394421

19  
h-index

752698

20  
g-index

22  
all docs

22  
docs citations

22  
times ranked

5841  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. <i>Cancer Cell</i> , 2022, 40, 289-300.e4.	16.8	148
2	Inferring gene expression from cell-free DNA fragmentation profiles. <i>Nature Biotechnology</i> , 2022, 40, 585-597.	17.5	63
3	Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer. <i>Cancer Research</i> , 2022, 82, 2838-2847.	0.9	14
4	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. <i>Cancer Cell</i> , 2021, 39, 346-360.e7.	16.8	422
5	Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. <i>Immunity</i> , 2021, 54, 586-602.e8.	14.3	80
6	Abstract PO-059: Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer. , 2021, , .		0
7	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2605-2616.	1.6	37
8	The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. <i>Cancer Cell</i> , 2021, 39, 1422-1437.e10.	16.8	102
9	Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. <i>Cancer Cell</i> , 2021, 39, 1594-1609.e12.	16.8	151
10	Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. <i>Cancer Discovery</i> , 2021, 11, 2968-2986.	9.4	116
11	KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. <i>Cancer Discovery</i> , 2020, 10, 1826-1841.	9.4	93
12	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 363-376.e13.	28.9	206
13	Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , 2020, 580, 245-251.	27.8	379
14	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 176-183.	13.2	201
15	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2849-2858.	7.0	74
16	Exosomes in the tumor microenvironment as mediators of cancer therapy resistance. <i>Molecular Cancer</i> , 2019, 18, 32.	19.2	271
17	Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA. <i>Cancer Discovery</i> , 2019, 9, 500-509.	9.4	143
18	Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer. <i>Cell</i> , 2017, 170, 352-366.e13.	28.9	335

#	ARTICLE	IF	CITATIONS
19	Linking primary and metastatic tumour re-initiation. <i>Nature Cell Biology</i> , 2015, 17, 542-543.	10.3	0
20	Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways. <i>Cell</i> , 2014, 159, 499-513.	28.9	659
21	Basal and stress-induced Hsp70 are modulated by ataxin-3. <i>Cell Stress and Chaperones</i> , 2012, 17, 729-742.	2.9	33
22	Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner. <i>Cancer Research</i> , 2010, 70, 9693-9702.	0.9	202